Skip to main content

Mobocertinib Dosage

Medically reviewed by Drugs.com. Last updated on Mar 12, 2024.

Applies to the following strengths: 40 mg

Usual Adult Dose for Non-Small Cell Lung Cancer

160 mg orally once a day
Duration of therapy: Until disease progression or unacceptable toxicity

Use: For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (as detected by a US FDA-approved test) whose disease has progressed on or after platinum-based chemotherapy

Renal Dose Adjustments

Mild to moderate renal dysfunction (estimated GFR 30 to 89 mL/min/1.73 m2): No adjustment recommended.
Severe renal dysfunction (estimated GFR less than 30 mL/min/1.73 m2): Data not available

Comments:

Liver Dose Adjustments

Mild or moderate liver dysfunction: No adjustment recommended.
Severe liver dysfunction: Data not available

Comments:

Dose Adjustments

Dose reduction levels for adverse reactions:


QTc Interval Prolongation and Torsades de Pointes:

Interstitial Lung Disease (ILD)/Pneumonitis:

Decreased Ejection Fraction or Heart Failure:

Diarrhea:

Increased Amylase or Lipase:

Other Adverse Reactions:

Graded per National Cancer Institute Common Terminology Criteria for Adverse Events

Coadministration with Moderate CYP450 3A Inhibitors: Concomitant use should be avoided.

Precautions

US BOXED WARNING:


CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

General:

Monitoring:

Patient advice:

Frequently asked questions

More about mobocertinib

Patient resources

Other brands

Exkivity

Professional resources

Other brands

Exkivity

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.